U.K. biotech Immunocor expands in wake of Genentech deal;

 @FierceBiotech:  SEC hunting down traders who made a quick killing on Onyx shares. Report | Follow @FierceBiotech

 @JohnCFierce:  Orexo stakes out $500M market for new opioid-addiction drug. More | Follow @JohnCFierce

 @RyanMFierce:  Xoma staffers form biotech startup to advance blood pressure med. News | Follow @RyanMFierce

 @EmilyMFierce:  In case you missed it over the holiday... Scientists create first regulatory map of tuberculosis. Report | Follow @EmilyMFierce

> Fast on the heels of completing a discovery deal with Genentech, the U.K.'s Immunocore is expanding, adding 25 staffers and a new facility for their work. Story

> Theragenics has signed an agreement to get its brachytherapy seeds into Europe, in an effort to expand its market share as the company considers a buyout worth up to $71.4 million. Story

> The proxy outfit ISS has backed three of First Manhattan's 9 members nominatees to the board of Vivus ($VVUS), where First Manhattan is the largest shareholder and seeks greater control of the company's leadership. Report

> Paris-based Cellectis reported that the company's experimental T-cell therapy killed human leukemia cells that had been implanted in mice. Release

Medical Device News

 @FierceMedDev: Europe tables vote on tougher device regs. More | Follow @FierceMedDev

 @MarkHFierce:  We want your FMD Fierce 15 nominations. Send them in! More | Follow @MarkHFierce

 @DamianFierce: Theragenics has signed a deal to get its brachytherapy products on the market in the EU. Story | Follow @DamianFierce

 @MichaelGFierce: ICYMI: Avanir drops $110M on novel inhaled-delivery migraine device. Article | Follow @MichaelGFierce

>  India's move to modernize its medical device regulations appears close. More

> U.K. playing catch-up with proton-therapy devices. News

Pharma News

 @FiercePharma:  FDA to update generic labeling rules. Article | Follow @FiercePharma

 @CarlyHFierce: ICYMI: Glass particles trigger another Fresenius Kabi recall. Story | Follow @CarlyHFierce

>  Novartis' Lucentis gets its fourth approval in EU. News

> Orexo gets FDA approval for opioid addiction-fighting Zubsolv. Story

> Fresenius gets warning letter for India plant. More

Vaccines News

> Reliance on NIH threatens HIV vaccine funding. Story

> Polio discovery prompts Israeli vaccination push. More

> Merck KGaA: Lung cancer vaccine not dead. Article

> Study: Use of 2D barcodes could save healthcare $300M. News

> Novartis and Sanofi nab DoD vaccine contracts. Item

And Finally… ChemistDirect, a U.K. online pharmacy, has picked up $10 million in new investments from Atomico, Lepe Partners and DMG Media. Item

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

The result, which beats the 35% reported by KRAS rival Amgen, sets Mirati up to file for FDA approval of the drug in the second half of next year.

Scorpion is working on precision oncology 2.0, including making better drugs for known targets, hitting undruggable targets and discovering new ones.